I. Background

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

When a CGA is issued, it is posted on the IGL&C website (www.cybergrants.com/pfizer/knowledge) in the Grants Process section and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>☑ United States Only</th>
</tr>
</thead>
</table>

Applicant Eligibility Criteria:

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

More information on organizations eligible to apply directly for a grant can be found at http://www.pfizer.com/files/IGLC_OrganizationEligibility_effJuly2015.pdf.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.
III. Requirements

| Date CGA Issued: | August 16, 2016 |
| Clinical Area:   | Geriatric Oncology |
| **Specific Area of Interest for this CGA:** | It is our intent to provide an independent grant to an organization or organizations who will conduct a thorough educational needs assessment in the area of geriatric oncology. With a growing population of older adults with cancer (≥70 years old), there is a growing educational need in terms of how to properly assess these individuals and make treatment decisions in line with their individual needs. Health care providers need to be able to adjust their practice for older adult patients, taking into consideration factors such as: risk of falling, muscle weakness, fatigue, cognitive deficits, and declining immune system. The needs assessment should be focused on oncologists at academic medical centers and/or community cancer centers and clinics. Other multi-disciplinary health-care professionals and care-team members should also be included. Pfizer’s intent is for the results of the needs assessment to be shared with the entire medical community in order to enhance future medical education programs and close gaps in the quality of care for older adults with cancer. In addition, the results will be used to inform educational budget planning and future Call for Grant Applications (CGAs) and Request for Proposals (RFPs). |
| Examples of needs assessment questions that could be addressed: | • What gaps exist in the quality of care of older adult patients with cancer in terms of the differences between best possible available approaches and usual care?  
• What factors influence or trigger oncologists to change their usual standard of care based on chronologic or physiologic age?  
• What existing educational or decision-support resources are most used by oncologists today and what new resources may be needed to determine appropriate assessment and treatment decisions?  
• What is the awareness of geriatric assessment tools? How do oncologists perceive geriatric assessment in their practice?  
• How comfortable or confident are practitioners in caring for older adult patients with cancer and how is the increasing availability of novel therapeutics impacting this comfort/confidence?  
• How comfortable or confident are practitioners in understanding or managing the risk of falling, muscle weakness, fatigue, cognitive deficits, declining immune system, etc, in older adult patients with cancer?  
• What are the factors that influence the motivation of oncologists to learn and improve their practice as it relates to this clinical area and patient population?  
• For questions related to new regimens, duration of therapy, switching of therapies, what are the educational needs of oncologists when it comes to caring for older adults with cancer?  
• What educational resources may be helpful in the interplay between the older adult cancer patient and the oncologist in decision-making about therapies?  
• How could tools such as treatment-pathways or EMR-based decision-support be utilized to improve practice in this clinical area?  
• What are the barriers to adoption of new treatment options in this patient population?  
• In rapidly advancing areas of medicine, when guidelines lag behind the science, what are the most trusted sources of evidence-based information and the most trusted sources for treatment recommendations?  
• How does the aging population affect the future of cancer care? |


<table>
<thead>
<tr>
<th><strong>Expected Approximate Monetary Range of Grant Applications:</strong></th>
<th>Individual projects requesting up to $250,000 will be considered. The total available budget related to this CGA is $250,000. The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Dates:</strong></td>
<td>CGA release date: August 16, 2016 Grant application due date: October 12, 2016 Please note the deadline is midnight Eastern Time (New York, GMT -5). Anticipated Grant Award Notification Date: November 18, 2016 Grants distributed following execution of fully signed Letter of Agreement Period of Performance: Up to 6 months. Study report must be available to Pfizer, for internal use only, no later than 6/1/17 in order to inform future grant planning. Timeline for publication in journals, web-posting, or other public distribution strategies may extend past this date</td>
</tr>
<tr>
<td><strong>How to Submit:</strong></td>
<td>Please go to the specific application log-in page and sign in. First-time users should click “REGISTER NOW”. Select the following Educational Area: CGA- Geriatric Oncology NA Requirements for submission: Complete all required sections of the online application and upload the completed CGA template (see Appendix). If you encounter any technical difficulties with the grant management system, please click the “Need Support?” link at the bottom of the page. IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.</td>
</tr>
<tr>
<td><strong>Questions:</strong></td>
<td>If you have questions regarding this CGA, please direct them in writing to Derek Warnick at <a href="mailto:derek.warnick@pfizer.com">derek.warnick@pfizer.com</a>, with the subject line “CGA- Geriatric Oncology NA”</td>
</tr>
<tr>
<td><strong>Mechanism by which Applicants will be Notified:</strong></td>
<td>All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification or to make a summary presentation during the review period.</td>
</tr>
</tbody>
</table>

**IV. Terms and Conditions**

1. This CGA does not commit Pfizer or its partners to award a grant or a grant of any particular size if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.
2. Pfizer reserves the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety, if it determines it is in the best interest of Pfizer to do so.

3. For compliance reasons and in fairness to all applicants, all communications about the CGA must come exclusively to Pfizer IGL&C. Failure to comply will disqualify applicants.

4. Consistent with its commitment to openness and transparency, Pfizer reports education grants provided to medical, scientific, and patient organizations in the United States. Pfizer reserves the right to announce the details of successful grant application(s) by whatever means insures transparency, such as on the Pfizer website, in presentations, and/or in other public media.

5. Pfizer reserves the right to share with organizations that may be interested in contacting you for further information (e.g., possible collaborations) the title of your proposed project and the name, address, telephone number, and e-mail address of the applicant from the requesting organization.

6. To comply with 42 U.S.C. § 1320a-7h and 42 C.F.R. §§ 403.900-.914 (the Sunshine Act), Provider (sponsor) must provide to Pfizer specific information for the U.S.-licensed physicians and U.S. teaching hospitals (“Covered Recipients,” as defined by applicable law) to whom Provider (sponsor) furnished payments or other transfers of value from the original independent grant awarded by Pfizer. Those payments or transfers-of-value include compensation, reimbursement for expenses, and meals provided to faculty (planners, speakers, investigators, project leads, etc.) and “items of value” (items that possess a discernable value on the open market, such as textbooks) provided to faculty and participants, if those faculty and/or participants meet the definition of Covered Recipient. Provider (sponsor) must submit the required information during the reconciliation process or earlier, upon Pfizer’s request, so Pfizer can meet Sunshine Act reporting commitments. Be advised that Pfizer will not make any payments to any individuals; grant funding shall be paid directly to Provider (sponsor).

Frequently Asked Questions related to IGLC’s Sunshine Act Reporting Requirements are available on our website (http://www.pfizer.com/files/IGLCsunshineFAQ_updatedJan2016.pdf).

7. No portion of a Pfizer independent grant may be used for food and/or beverages for learners and/or participants in any capacity. Provider (sponsor) will be required to certify during the reconciliation process and/or the periodic collection of Sunshine reporting that funds were not used for food and/or beverages for learners and/or participants.

8. In the performance of all activities related to an independent grant, the Provider (sponsor) and all participants must comply with all applicable Global Trade Control Laws. “Global Trade Control Laws” include, but are not limited to, U.S. Export Administration Regulations; the International Traffic in Arms Regulations; EU export controls on dual-use goods and technology; Financial Sanctions Laws and Restrictive Measures imposed within the framework of the CFSP - Treaty on European Union; and the economic sanctions rules and regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control.

Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
C. Study goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Background/need for the study
F. Target Population
G. Project Design and Methods: Include a description of the planned study and analysis methods; assessments should include multiple sources of information
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
I. Dissemination Plan: Describe how the needs assessment findings will be broadly disseminated. Proposals must include a plan for public domain availability of the study results.
J. Project timeline: Including timeline for report preparation, publication submission, and/or public presentation
K. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
L. References (outside the 15-page limit)
   • There is no designated format for references
M. Budget (See template available in application)
   • While estimating your budget please keep the following items in mind:
     • Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
     • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
     • A separate Excel file should be uploaded. This does not count toward the page limit.
       • An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
       • At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 15-page limit exclusive of references. If extensive, references may be included on 1-2 additional pages.